BUZZ-Valeant Pharmaceuticals: May need to restate earnings - WSJ

Mon Feb 22, 2016 5:30pm EST
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]


** Embattled Canadian drugmaker's U.S.-listed shares down 7.8 pct at $70.02 in extended trading

** Valeant may need to restate its earnings based on the results of an internal probe, the Wall Street Journal reported, citing people familiar with the matter (

** Potential revision to earnings may concern revenue from sales to distributor Philidor Rx Services

** Period in question is late 2014 and early 2015

** Company's board has been meeting in recent days, but a decision on the potential revision hasn't yet been finalized

** Valeant's U.S.-listed shares closed down 10.7 pct at $75.92 on Monday after it was reported interim CEO Howard Schiller used company's jet three times in past month with his family and friends to fly to a small regional airport in Montrose, Colorado near his Telluride ski-house (

** Up to Monday's close, U.S. stock had fallen 62 pct over past 12 months